GlassScriptPhysician profile
Kevin A Agrest
NPI 1386625606
$12,899.88
in general payments reported to CMS, 2019-2025
42 companies · $2,341 in 2025
The $2,341 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,617 · 2020: $1,016 · 2021: $1,670 · 2022: $1,974 · 2023: $1,907 · 2024: $2,375 · 2025: $2,341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,623.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,207.20 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $1,778.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,246.55 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,052.02 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,045.71 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Abbott Laboratories | $774.13 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Pfizer INC. | $658.41 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $529.92 | 2021-2025 | |
| Amgen INC. | $395.88 | 2019-2025 | Repatha, Otezla, Evenity |
| Abbvie INC. | $361.40 | 2021-2024 | Vraylar |
| Janssen Pharmaceuticals, INC | $311.62 | 2019-2023 | Xarelto |
| Sanofi-Aventis U.S. LLC | $295.14 | 2019-2023 | |
| Amarin Pharma, INC. | $259.34 | 2019-2022 | |
| Dexcom, INC. | $213.29 | 2021-2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $202.09 | 2023-2025 | Cologuard Collection Kit |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Agrest listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.